New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

Molecular Breast Imaging is a highly promising novel methodology for breast cancer detection. Preliminary patient studies with our dual-detector system indicate that this system is capable of reliably detecting very small (5-10 mm) malignant lesions in the breast. Besides the usefulness of Molecular Breast Imaging for tumor detection, we speculate that tumor uptake and washout may be predictors to response to neoadjuvant therapy for patients with the diagnosis of breast cancer. We propose that in patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy that molecular breast imaging is an accurate test for assessing response rate to neoadjuvant therapy.

Key facts

Study ID

NCT00566085

Run by

Mayo Clinic

People needed

20

Starts

2008-01-01

Expected to finish

2010-02-01

Last updated by the study team

2012-01-06

Who can join

Age: 18 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women age 18 - 90
• Women with breast cancer scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy
• Women who have undergone any breast imaging procedure, and in whom a repeat imaging procedure is planned prior to definite surgery

You may not qualify if…

• Pregnant or lactating
• Unable to understand or sign a consent form
• Physically unable to sit upright and still for 40 minutes

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.